BioDtech, Inc. Issued New United States Patent
News Feb 20, 2013
The patent, entitled “Enhancing Endotoxin Detection,” covers the company’s EndoPrepTM and ESPTM technologies for the use of accurate endotoxin detection in biopharmaceuticals and human plasma, respectively.
This is the second patent issued to BioDtech for the protection of their intellectual property designed to detect Gram-negative bacteria in a sample, then remove and neutralize endotoxins, depending on their specific requirements.
“The technology covered by this patent has broad applications that enable better safety and efficacy for biotherapeutics and monitoring of inflammation based diseases,” stated Dr. Michael Pepe PhD, President and Chief Executive Officer of BioDtech. “The company is currently pursuing the potential use of this technology for the quality control and production of biotherapeutics as well as diagnostic monitoring of gastrointestinal diseases and Gram-negative bacterial infections,” added Pepe.
Batavia Biosciences Teams Up with International Consortium to Support Polio EradicationNews
Batavia Biosciences announces its partnership with an international consortium coordinated by PATH aiming to develop and manufacture safer novel oral poliovirus vaccines (nOPV).READ MORE
Energy Drinks Pose Health Risk for YoungstersNews
In a nationwide survey of Canadian youth, over half of those who had ever consumed an energy drink had reported experiencing an adverse health event, including rapid heartbeat, nausea, and in rare cases, seizures. Currently, Canadian legislation is meant to prohibit energy drinks from being marketed to children and energy drinks are not recommend to be used by people participating in sporting activities.READ MORE
Pharmaceutical Pollution Drives Antimicrobial ResistanceNews
In urban streams, persistent pharmaceutical pollution can cause aquatic microbial communities to become resistant to drugs.READ MORE
Comments | 0 ADD COMMENT
Precision Medicine & Biomarkers Leaders Summit: USA
May 07 - May 08, 2018